CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 132 enrolled
Drug / intervention
Placebo oral capsule +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03524339
NCT03524339Phase 3Completed
CompareCT.gov

Perioperative Administration of Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery

University Hospitals Cleveland Medical Center·interventional·Posted May 14, 2018·Updated Nov 8, 2021

In Brief

A Phase 3 clinical trial evaluating Placebo oral capsule and Tamsulosin for Urinary Retention and 3 related conditions. Completed, enrolled 132 participants across 2 sites.

Detailed Summary

This is a placebo controlled randomized controlled trial of perioperative use of tamsulosin to prevent postoperative urinary retention in female pelvic reconstructive surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Retention, Lower Urinary Tract Symptoms, Stress Urinary Incontinence, Pelvic Organ Prolapse
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMay 14, 2018
Enrollment StartAug 1, 2018
Primary CompletionJun 9, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.1 years ago

Interventions

Placebo oral capsuledrug

Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.

Tamsulosindrug

Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.